BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S, Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2008;19:1847-1852. [PMID: 18567607 DOI: 10.1093/annonc/mdn395] [Cited by in Crossref: 153] [Cited by in F6Publishing: 133] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Hill SJ, Clark AP, Silver DP, Livingston DM. BRCA1 pathway function in basal-like breast cancer cells. Mol Cell Biol 2014;34:3828-42. [PMID: 25092866 DOI: 10.1128/MCB.01646-13] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
2 Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press) 2016;8:93-107. [PMID: 27284266 DOI: 10.2147/BCTT.S69488] [Cited by in Crossref: 37] [Cited by in F6Publishing: 91] [Article Influence: 7.4] [Reference Citation Analysis]
3 Gwe Ahn S, Ah Lee S, Woo Lee H, Min Lee H, Jeong J. In vitro chemoresponse assay based on the intrinsic subtypes in breast cancer. Jpn J Clin Oncol 2014;44:624-31. [PMID: 24803548 DOI: 10.1093/jjco/hyu057] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
4 Cheng S, Huang Y, Lou C, He Y, Zhang Y, Zhang Q. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation. Cancer Biol Ther 2019;20:328-37. [PMID: 30336071 DOI: 10.1080/15384047.2018.1529101] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
5 Moncharmont C, Auberdiac P, Mélis A, Afqir S, Pacaut C, Chargari C, Merrouche Y, Magné N. [Cisplatin or carboplatin, that is the question]. Bull Cancer 2011;98:164-75. [PMID: 21382796 DOI: 10.1684/bdc.2011.1307] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
6 Franzoi MA, Saúde-Conde R, Ferreira SC, Eiger D, Awada A, de Azambuja E. Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. Breast 2021;57:86-94. [PMID: 33799232 DOI: 10.1016/j.breast.2021.03.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010;12 Suppl 2:S3. [PMID: 21050424 DOI: 10.1186/bcr2574] [Cited by in Crossref: 136] [Cited by in F6Publishing: 133] [Article Influence: 12.4] [Reference Citation Analysis]
8 Dizdar O, Altundag K. Current and emerging treatment options in triple-negative breast cancer. Oncol Rev 2010;4:5-13. [DOI: 10.1007/s12156-009-0031-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
9 Cleere DW. Triple-negative breast cancer: a clinical update. Community Oncology 2010;7:203-11. [DOI: 10.1016/s1548-5315(11)70394-1] [Cited by in Crossref: 25] [Article Influence: 2.3] [Reference Citation Analysis]
10 Li Q, Li Q, Zhang P, Yuan P, Wang J, Ma F, Luo Y, Fan Y, Cai R, Xu B. A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes. Cancer Biol Ther 2015;16:1746-53. [PMID: 26466918 DOI: 10.1080/15384047.2015.1095400] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
11 Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157-167. [PMID: 21076464 DOI: 10.1038/modpathol.2010.200] [Cited by in Crossref: 368] [Cited by in F6Publishing: 331] [Article Influence: 33.5] [Reference Citation Analysis]
12 Irshad S, Ellis P, Tutt A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Current Opinion in Oncology 2011;23:566-77. [DOI: 10.1097/cco.0b013e32834bf8ae] [Cited by in Crossref: 53] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
13 Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. The Breast 2010;19:312-21. [DOI: 10.1016/j.breast.2010.03.026] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 11.5] [Reference Citation Analysis]
14 Parmar V, Nair NS, Thakkar P, Chitkara G. Molecular Biology in the Breast Clinics-Current status and future perspectives. Indian J Surg Oncol 2021;12:7-20. [PMID: 33994723 DOI: 10.1007/s13193-019-00954-1] [Reference Citation Analysis]
15 Park J, Morley TS, Scherer PE. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med 2013;5:935-48. [DOI: 10.1002/emmm.201202006] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
16 Yin Y, Zhang P, Xu BH, Zhang BL, Li Q, Yuan P, Cai RG, Wang JY, Wang X, Xu XZ. Unfavorable pathological complete response rate of neoadjuvant chemotherapy epirubicin plus taxanes for locally advanced triple-negative breast cancer. J Huazhong Univ Sci Technolog Med Sci 2013;33:262-5. [PMID: 23592141 DOI: 10.1007/s11596-013-1108-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
17 Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, Rochlitz C, Zanetti-Dällenbach R. Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience. Oncotarget 2017;8:75617-26. [PMID: 29088896 DOI: 10.18632/oncotarget.18118] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
18 Staudacher L, Cottu P, Diéras V, Vincent-salomon A, Guilhaume M, Escalup L, Dorval T, Beuzeboc P, Mignot L, Pierga J. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience. Annals of Oncology 2011;22:848-56. [DOI: 10.1093/annonc/mdq461] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
19 Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012;4:195-210. [PMID: 22754593 DOI: 10.1177/1758834012444711] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
20 Atipairin A, Ratanaphan A. In Vitro Enhanced Sensitivity to Cisplatin in D67Y BRCA1 RING Domain Protein. Breast Cancer (Auckl) 2011;5:201-8. [PMID: 22084573 DOI: 10.4137/BCBCR.S8184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
21 Petrelli F, Cabiddu M, Ghilardi M, Barni S. Current data of targeted therapies for the treatment of triple-negative advanced breast cancer: empiricism or evidence-based? Expert Opin Investig Drugs 2009;18:1467-77. [PMID: 19737114 DOI: 10.1517/13543780903222268] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
22 Dawood S. Triple-negative breast cancer: epidemiology and management options. Drugs 2010;70:2247-58. [PMID: 21080741 DOI: 10.2165/11538150-000000000-00000] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 7.3] [Reference Citation Analysis]
23 Hahnen E, Lederer B, Hauke J, Loibl S, Kröber S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, Paepke S, Gerber B, Kümmel S, Schem C, Neidhardt G, Huober J, Rhiem K, Costa S, Altmüller J, Hanusch C, Thiele H, Müller V, Nürnberg P, Karn T, Nekljudova V, Untch M, von Minckwitz G, Schmutzler RK. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial. JAMA Oncol 2017;3:1378-85. [PMID: 28715532 DOI: 10.1001/jamaoncol.2017.1007] [Cited by in Crossref: 150] [Cited by in F6Publishing: 136] [Article Influence: 37.5] [Reference Citation Analysis]
24 Greenberg S, Rugo HS. Challenging Clinical Scenarios: Treatment of Patients With Triple-Negative or Basal-Like Metastatic Breast Cancer. Clinical Breast Cancer 2010;10:S20-9. [DOI: 10.3816/cbc.2010.s.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Chen S, Greasley S, Ong Z, Naruphontjirakul P, Page S, Hanna J, Redpath A, Tsigkou O, Rankin S, Ryan M, Porter A, Jones J. Biodegradable zinc-containing mesoporous silica nanoparticles for cancer therapy. Materials Today Advances 2020;6:100066. [DOI: 10.1016/j.mtadv.2020.100066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
26 Galanina N, Bossuyt V, Harris LN. Molecular Predictors of Response to Therapy for Breast Cancer. The Cancer Journal 2011;17:96-103. [DOI: 10.1097/ppo.0b013e318212dee3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.1] [Reference Citation Analysis]
27 Kotsori A, Dolly S, Sheri A, Parton M, Shaunak N, Ashley S, Walsh G, Johnston S, Smith I. Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer? Oncology 2010;79:331-6. [DOI: 10.1159/000323175] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
28 Nhukeaw T, Temboot P, Hansongnern K, Ratanaphan A. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine. BMC Cancer 2014;14:73. [PMID: 24507701 DOI: 10.1186/1471-2407-14-73] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
29 Villarreal-Garza C, Khalaf D, Bouganim N, Clemons M, Peña-Curiel O, Baez-Revueltas B, Kiss A, Kassam F, Enright K, Verma S, Pritchard K, Myers J, Dent R. Platinum-based chemotherapy in triple-negative advanced breast cancer. Breast Cancer Res Treat 2014;146:567-72. [PMID: 25001611 DOI: 10.1007/s10549-014-3033-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
30 Baek DW, Park JY, Lee SJ, Chae YS. Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. Yeungnam Univ J Med 2020;37:230-5. [PMID: 31962039 DOI: 10.12701/yujm.2019.00423] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Wu K, Yang Q, Liu Y, Wu A, Yang Z. Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy. World J Surg Oncol 2014;12:95. [PMID: 24731479 DOI: 10.1186/1477-7819-12-95] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
32 Oakman C, Bessi S, Zafarana E, Galardi F, Biganzoli L, Di Leo A. Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res 2009;11:205. [PMID: 19435470 DOI: 10.1186/bcr2238] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
33 Shamseddine AI, Farhat FS. Platinum-based compounds for the treatment of metastatic breast cancer. Chemotherapy 2011;57:468-87. [PMID: 22248721 DOI: 10.1159/000334093] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
34 Lee YJ, Kim HS, Rim JH, Lee JY, Nam EJ, Kim SW, Kim S, Kim YT. Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer. BMC Cancer 2020;20:185. [PMID: 32131779 DOI: 10.1186/s12885-020-6688-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
35 Verma S, Provencher L, Dent R. Emerging trends in the treatment of triple-negative breast cancer in Canada: a survey. Curr Oncol 2011;18:180-90. [PMID: 21874117 DOI: 10.3747/co.v18i4.913] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
36 Engel JB, Martens T, Hahne JC, Häusler SF, Krockenberger M, Segerer S, Djakovic A, Meyer S, Dietl J, Wischhusen J, Honig A. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro. Anti-Cancer Drugs 2012;23:426-36. [DOI: 10.1097/cad.0b013e32834fb8ce] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
37 Kurebayashi J, Kanomata N, Moriya T, Kozuka Y, Watanabe M, Sonoo H. Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer 2010;10:568. [PMID: 20959018 DOI: 10.1186/1471-2407-10-568] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
38 Xu L, Yin S, Banerjee S, Sarkar F, Reddy KB. Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Mol Cancer Ther 2011;10:550-7. [PMID: 21252285 DOI: 10.1158/1535-7163.MCT-10-0571] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
39 Oakman C, Pestrin M, Cantisani E, Licitra S, Destefanis M, Biganzoli L, Di Leo A. Adjuvant chemotherapy – the dark side of clinical trials Have we learnt more? The Breast 2009;18:S18-24. [DOI: 10.1016/s0960-9776(09)70267-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
40 Shahin M, Safaei-Nikouei N, Lavasanifar A. Polymeric micelles for pH-responsive delivery of cisplatin. J Drug Target 2014;22:629-37. [PMID: 24878378 DOI: 10.3109/1061186X.2014.921925] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.1] [Reference Citation Analysis]
41 Lee J, Kim HH, Ro SM, Yang JH. Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer. PLoS One 2017;12:e0171605. [PMID: 28234911 DOI: 10.1371/journal.pone.0171605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
42 Engebraaten O, Vollan HK, Børresen-Dale AL. Triple-negative breast cancer and the need for new therapeutic targets. Am J Pathol. 2013;183:1064-1074. [PMID: 23920327 DOI: 10.1016/j.ajpath.2013.05.033] [Cited by in Crossref: 87] [Cited by in F6Publishing: 81] [Article Influence: 10.9] [Reference Citation Analysis]
43 Hurley J, Reis IM, Rodgers SE, Gomez-fernandez C, Wright J, Leone JP, Larrieu R, Pegram MD. The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients. Breast Cancer Res Treat 2013;138:783-94. [DOI: 10.1007/s10549-013-2497-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 43] [Article Influence: 6.0] [Reference Citation Analysis]
44 Tang Y, Zhu L, Li Y, Ji J, Li J, Yuan F, Wang D, Chen W, Huang O, Chen X, Wu J, Shen K, Loo WT, Chow LW. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med 2012;10 Suppl 1:S4. [PMID: 23046633 DOI: 10.1186/1479-5876-10-S1-S4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
45 Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010;16:53-61. [PMID: 20164691 DOI: 10.1097/PPO.0b013e3181d24ff7] [Cited by in Crossref: 184] [Cited by in F6Publishing: 105] [Article Influence: 16.7] [Reference Citation Analysis]
46 Periasamy VS, Alshatwi AA. Tea polyphenols modulate antioxidant redox system on cisplatin-induced reactive oxygen species generation in a human breast cancer cell. Basic Clin Pharmacol Toxicol 2013;112:374-84. [PMID: 23145928 DOI: 10.1111/bcpt.12035] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
47 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 127] [Article Influence: 47.7] [Reference Citation Analysis]
48 Cobleigh MA. Other options in the treatment of advanced breast cancer. Semin Oncol 2011;38 Suppl 2:S11-6. [PMID: 21600380 DOI: 10.1053/j.seminoncol.2011.04.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.3] [Reference Citation Analysis]
49 Wang Z, Xu L, Wang H, Li Z, Lu L, Li X, Zhang Q. Lobaplatin-based regimens outperform cisplatin for metastatic breast cancer after anthracyclines and taxanes treatment. Saudi J Biol Sci 2018;25:909-16. [PMID: 30108440 DOI: 10.1016/j.sjbs.2018.01.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
50 Lønning PE, Knappskog S. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene 2013;32:5315-30. [PMID: 23474753 DOI: 10.1038/onc.2013.48] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
51 Guarneri V, Conte P. Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy. Oncologist. 2009;14:645-656. [PMID: 19608638 DOI: 10.1634/theoncologist.2009-0078] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
52 Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, Santoro F, Wouters H, Russnes HG, Sørlie T, Tagliabue E, Børresen-Dale AL; FEMME Consortium. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010;4:209-29. [PMID: 20537966 DOI: 10.1016/j.molonc.2010.04.006] [Cited by in Crossref: 181] [Cited by in F6Publishing: 174] [Article Influence: 16.5] [Reference Citation Analysis]
53 Frasci G, D’aiuto G, Comella P, D’aiuto M, Di Bonito M, Ruffolo P, Iodice G, Petrillo A, Lastoria S, Oliviero P, Capasso I, Montella M, Siani C, Santangelo M, Vizioli L, Comella G. Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908. Annals of Oncology 2010;21:707-16. [DOI: 10.1093/annonc/mdp356] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
54 Kordek R, Potemski P, Kusinska R, Pluciennik E, Bednarek A. Basal keratin expression in breast cancer by quantification of mRNA and by immunohistochemistry. J Exp Clin Cancer Res 2010;29:39. [PMID: 20426817 DOI: 10.1186/1756-9966-29-39] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
55 Yi SY, Ahn JS, Uhm JE, Lim DH, Ji SH, Jun HJ, Kim KH, Chang MH, Park MJ, Cho EY, Choi YL, Park YH, Im YH. Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype. BMC Cancer 2010;10:527. [PMID: 20920367 DOI: 10.1186/1471-2407-10-527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
56 Vaklavas C, Forero-Torres A. How do I treat "triple-negative" disease. Curr Treat Options Oncol 2011;12:369-88. [PMID: 22048876 DOI: 10.1007/s11864-011-0168-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
57 Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009;124:1457-62. [PMID: 19065658 DOI: 10.1002/ijc.24090] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
58 Lai CPT, Yeong JPS, Tan AS, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH. Evaluation of phospho-histone H3 in Asian triple-negative breast cancer using multiplex immunofluorescence. Breast Cancer Res Treat 2019;178:295-305. [PMID: 31410680 DOI: 10.1007/s10549-019-05396-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
59 Liu J, Xiao Y, Wei W, Guo JX, Liu YC, Huang XH, Zhang RX, Wu YJ, Zhou J. Clinical efficacy of administering oxaliplatin combined with S-1 in the treatment of advanced triple-negative breast cancer. Exp Ther Med 2015;10:379-85. [PMID: 26170966 DOI: 10.3892/etm.2015.2489] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
60 Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat 2014;144:223-32. [PMID: 24557340 DOI: 10.1007/s10549-014-2876-z] [Cited by in Crossref: 81] [Cited by in F6Publishing: 78] [Article Influence: 11.6] [Reference Citation Analysis]
61 Tian M, Zhong Y, Zhou F, Xie C, Zhou Y, Liao Z. Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis. Oncol Lett 2015;9:2825-32. [PMID: 26137155 DOI: 10.3892/ol.2015.3072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
62 Gregório AC, Lacerda M, Figueiredo P, Simões S, Dias S, Moreira JN. Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer. Pathol Oncol Res 2018;24:701-16. [PMID: 28913723 DOI: 10.1007/s12253-017-0307-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
63 Franchina T, Adamo B, Ricciardi GR, Caristi N, Agostino RM, Proto C, Adamo V. Activity of pegylated liposomal doxorubicin in combination with gemcitabine in triple negative breast cancer with skin involvement: two case reports. Cancer Biol Ther 2012;13:472-6. [PMID: 22526226 DOI: 10.4161/cbt.19593] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
64 Livasy CA. Triple-Negative Breast Carcinoma. Surg Pathol Clin 2009;2:247-61. [PMID: 26838321 DOI: 10.1016/j.path.2009.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
65 Oakman C, Moretti E, Galardi F, Biagioni C, Santarpia L, Biganzoli L, Di Leo A. Adjuvant systemic treatment for individual patients with triple negative breast cancer. The Breast 2011;20:S135-41. [DOI: 10.1016/s0960-9776(11)70311-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
66 Al-bahlani S, Al-lawati H, Al-adawi M, Al-abri N, Al-dhahli B, Al-adawi K. Fatty acid synthase regulates the chemosensitivity of breast cancer cells to cisplatin-induced apoptosis. Apoptosis 2017;22:865-76. [DOI: 10.1007/s10495-017-1366-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
67 Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014;102:808-815.e1. [PMID: 25044080 DOI: 10.1016/j.fertnstert.2014.06.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
68 Wang S, Oh DY, Leventaki V, Drakos E, Zhang R, Sahin AA, Resetkova E, Edgerton ME, Wu W, Claret FX. MicroRNA-17 acts as a tumor chemosensitizer by targeting JAB1/CSN5 in triple-negative breast cancer. Cancer Lett 2019;465:12-23. [PMID: 31473252 DOI: 10.1016/j.canlet.2019.08.016] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
69 Jin J, Zhang W, Ji W, Yang F, Guan X. Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy. Cancer Biol Ther 2017;18:369-78. [PMID: 28494179 DOI: 10.1080/15384047.2017.1323582] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
70 Shastry M, Yardley DA. Updates in the treatment of basal/triple-negative breast cancer. Curr Opin Obstet Gynecol 2013;25:40-8. [PMID: 23222093 DOI: 10.1097/GCO.0b013e32835c1633] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
71 Taha FM, Zeeneldin AA, Helal AM, Gaber AA, Sallam YA, Ramadan H, Moneer MM. Prognostic value of serum vascular endothelial growth factor in Egyptian females with metastatic triple negative breast cancer. Clin Biochem. 2009;42:1420-1426. [PMID: 19576877 DOI: 10.1016/j.clinbiochem.2009.06.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
72 Hill SJ, Rolland T, Adelmant G, Xia X, Owen MS, Dricot A, Zack TI, Sahni N, Jacob Y, Hao T, McKinney KM, Clark AP, Reyon D, Tsai SQ, Joung JK, Beroukhim R, Marto JA, Vidal M, Gaudet S, Hill DE, Livingston DM. Systematic screening reveals a role for BRCA1 in the response to transcription-associated DNA damage. Genes Dev 2014;28:1957-75. [PMID: 25184681 DOI: 10.1101/gad.241620.114] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 8.9] [Reference Citation Analysis]
73 Rubovszky G, Udvarhelyi N, Horváth Z, Láng I, Kásler M. A tripla-negatív emlőkarcinóma – irodalmi áttekintés. Magyar Onkológia 2010;54:325-35. [DOI: 10.1556/monkol.54.2010.4.6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
74 Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 2011;61:31-49. [PMID: 21205831 DOI: 10.3322/caac.20095] [Cited by in Crossref: 132] [Cited by in F6Publishing: 117] [Article Influence: 13.2] [Reference Citation Analysis]
75 Fan Y, Xu BH, Yuan P, Ma F, Wang JY, Ding XY, Zhang P, Li Q, Cai RG. Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer. Ann Oncol 2013;24:1219-25. [PMID: 23223332 DOI: 10.1093/annonc/mds603] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 5.9] [Reference Citation Analysis]
76 Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer--current status and future directions. Ann Oncol. 2009;20:1913-1927. [PMID: 19901010 DOI: 10.1093/annonc/mdp492] [Cited by in Crossref: 357] [Cited by in F6Publishing: 326] [Article Influence: 29.8] [Reference Citation Analysis]
77 Kwok JM, Peck B, Monteiro LJ, Schwenen HD, Millour J, Coombes RC, Myatt SS, Lam EW. FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res 2010;8:24-34. [PMID: 20068070 DOI: 10.1158/1541-7786.MCR-09-0432] [Cited by in Crossref: 141] [Cited by in F6Publishing: 96] [Article Influence: 12.8] [Reference Citation Analysis]
78 Nasr KE, Osman MA, Elkady MS, Ellithy MA. Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study. Ann Transl Med. 2015;3:284. [PMID: 26697444 DOI: 10.3978/j.issn.2305-5839.2015.11.14] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
79 Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, Broadwater G, Blackwell K. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Clin Breast Cancer 2013;13:416-20. [PMID: 24099649 DOI: 10.1016/j.clbc.2013.08.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
80 Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev 2016;50:129-41. [PMID: 27665540 DOI: 10.1016/j.ctrv.2016.09.004] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 8.2] [Reference Citation Analysis]
81 Cohen MS, Cai S, Xie Y, Forrest ML. A novel intralymphatic nanocarrier delivery system for cisplatin therapy in breast cancer with improved tumor efficacy and lower systemic toxicity in vivo. Am J Surg 2009;198:781-6. [PMID: 19969129 DOI: 10.1016/j.amjsurg.2009.07.032] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
82 Hahne JC, Schmidt H, Meyer SR, Engel JB, Dietl J, Honig A. Anti-tumour activity of phosphoinositide-3-kinase antagonist AEZS 126 in models of triple-negative breast cancer. J Cancer Res Clin Oncol 2013;139:905-14. [PMID: 23440492 DOI: 10.1007/s00432-013-1399-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Zhang W, Tung C. Lysosome Enlargement Enhanced Photochemotherapy Using a Multifunctional Nanogel. ACS Appl Mater Interfaces 2018;10:4343-8. [DOI: 10.1021/acsami.7b16575] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
84 El Saghir NS, Tfayli A, Hatoum HA, Nachef Z, Dinh P, Awada A. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol. 2011;80:433-449. [PMID: 21330148 DOI: 10.1016/j.critrevonc.2011.01.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
85 Kim H, Jung K, Im S, Im Y, Kang S, Park K, Lee S, Kim S, Lee K, Ahn J, Kim S, Sohn J. Multicentre phase II trial of bevacizumab combined with docetaxel–carboplatin for the neoadjuvant treatment of triple-negative breast cancer (KCSG BR-0905). Annals of Oncology 2013;24:1485-90. [DOI: 10.1093/annonc/mds658] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
86 Tan AS, Yeong JPS, Lai CPT, Ong CHC, Lee B, Lim JCT, Thike AA, Iqbal J, Dent RA, Lim EH, Tan PH. The role of Ki-67 in Asian triple negative breast cancers: a novel combinatory panel approach. Virchows Arch 2019;475:709-25. [PMID: 31407032 DOI: 10.1007/s00428-019-02635-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
87 Travis LB, Fossa SD, Sesso HD, Frisina RD, Herrmann DN, Beard CJ, Feldman DR, Pagliaro LC, Miller RC, Vaughn DJ, Einhorn LH, Cox NJ, Dolan ME; Platinum Study Group. Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics. J Natl Cancer Inst 2014;106:dju044. [PMID: 24623533 DOI: 10.1093/jnci/dju044] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
88 Gerratana L, Fanotto V, Pelizzari G, Agostinetto E, Puglisi F. Do platinum salts fit all triple negative breast cancers? Cancer Treat Rev 2016;48:34-41. [PMID: 27343437 DOI: 10.1016/j.ctrv.2016.06.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
89 Tyagi M, Patro BS. Salinomycin reduces growth, proliferation and metastasis of cisplatin resistant breast cancer cells via NF-kB deregulation. Toxicol In Vitro 2019;60:125-33. [PMID: 31077746 DOI: 10.1016/j.tiv.2019.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
90 Gelmon K, Dent R, Mackey J, Laing K, Mcleod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Annals of Oncology 2012;23:2223-34. [DOI: 10.1093/annonc/mds067] [Cited by in Crossref: 112] [Cited by in F6Publishing: 103] [Article Influence: 12.4] [Reference Citation Analysis]
91 Fornier M, Fumoleau P. The paradox of triple negative breast cancer: novel approaches to treatment. Breast J 2012;18:41-51. [PMID: 22098334 DOI: 10.1111/j.1524-4741.2011.01175.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
92 Somlo G, Lau SK, Frankel P, Hsieh HB, Liu X, Yang L, Krivacic R, Bruce RH. Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res Treat. 2011;128:155-163. [PMID: 21499685 DOI: 10.1007/s10549-011-1508-0] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 8.6] [Reference Citation Analysis]
93 Li SX, Sjolund A, Harris L, Sweasy JB. DNA repair and personalized breast cancer therapy. Environ Mol Mutagen 2010;51:897-908. [PMID: 20872853 DOI: 10.1002/em.20606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
94 Davison Z, de Blacquière GE, Westley BR, May FE. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia 2011;13:504-15. [PMID: 21677874 DOI: 10.1593/neo.101590] [Cited by in Crossref: 83] [Cited by in F6Publishing: 84] [Article Influence: 8.3] [Reference Citation Analysis]
95 Phan B, Majid S, Ursu S, de Semir D, Nosrati M, Bezrookove V, Kashani-Sabet M, Dar AA. Tumor suppressor role of microRNA-1296 in triple-negative breast cancer. Oncotarget 2016;7:19519-30. [PMID: 26799586 DOI: 10.18632/oncotarget.6961] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
96 Brunetto AT, Sarker D, Papadatos-Pastos D, Fehrmann R, Kaye SB, Johnston S, Allen M, De Bono JS, Swanton C. A retrospective analysis of clinical outcome of patients with chemo-refractory metastatic breast cancer treated in a single institution phase I unit. Br J Cancer 2010;103:607-12. [PMID: 20664586 DOI: 10.1038/sj.bjc.6605812] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
97 Arslan C, Dizdar O, Altundag K. Pharmacotherapy of triple-negative breast cancer. Expert Opinion on Pharmacotherapy 2009;10:2081-93. [DOI: 10.1517/14656560903117309] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
98 Bozionelou V, Kalbakis K, Vamvakas L, Agelaki S, Androulakis N, Kalykaki A, Georgoulias V, Mavroudis D. A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer. Cancer Chemother Pharmacol 2009;64:785-91. [DOI: 10.1007/s00280-009-0928-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Lim S, Kim Y, Lee SB, Kang HG, Kim DH, Park JW, Chung D, Kong H, Yoo KH, Kim Y, Han W, Chun KH, Park JH. Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer. Oncogenesis 2020;9:91. [PMID: 33041328 DOI: 10.1038/s41389-020-00275-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
100 Atipairin A, Canyuk B, Ratanaphan A. Cisplatin Affects the Conformation of Apo Form, not Holo Form, of BRCA1 RING Finger Domain and Confers Thermal Stability. Chemistry & Biodiversity 2010;7:1949-67. [DOI: 10.1002/cbdv.200900308] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
101 Abdal Dayem A, Choi HY, Yang GM, Kim K, Saha SK, Cho SG. The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. Nutrients 2016;8:E581. [PMID: 27657126 DOI: 10.3390/nu8090581] [Cited by in Crossref: 65] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
102 Bartsch R, Ziebermayr R, Zielinski CC, Steger GG. Triple-negative breast cancer. Wien Med Wochenschr 2010;160:174-81. [PMID: 20473728 DOI: 10.1007/s10354-010-0773-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
103 Guan X, Ma F, Fan Y, Zhu W, Hong R, Xu B. Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anticancer Drugs 2015;26:894-901. [PMID: 26086398 DOI: 10.1097/CAD.0000000000000260] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
104 Rastelli F, Biancanelli S, Falzetta A, Martignetti A, Casi C, Bascioni R, Giustini L, Crispino S. Triple-Negative Breast Cancer: Current State of the Art. Tumori Journal 2018;96:875-88. [DOI: 10.1177/548.6505] [Cited by in Crossref: 46] [Cited by in F6Publishing: 13] [Article Influence: 15.3] [Reference Citation Analysis]
105 Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M. Methylation of O 6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. Breast Cancer Res Treat 2012;134:131-7. [DOI: 10.1007/s10549-011-1945-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
106 Gogineni K, DeMichele A. Current approaches to the management of Her2-negative metastatic breast cancer. Breast Cancer Res 2012;14:205. [PMID: 22429313 DOI: 10.1186/bcr3064] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
107 Ademuyiwa FO, Ellis MJ, Ma CX. Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. J Oncol 2013;2013:219869. [PMID: 23983689 DOI: 10.1155/2013/219869] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
108 Yerushalmi R, Hayes MM, Gelmon KA, Chia S, Bajdik C, Norris B, Speers C, Hassell P, O'reilly SE, Allan S, Shenkier TN. A Phase II Trial of a Neoadjuvant Platinum Regimen for Locally Advanced Breast Cancer: Pathologic Response, Long-Term Follow-up, and Correlation With Biomarkers. Clinical Breast Cancer 2009;9:166-72. [DOI: 10.3816/cbc.2009.n.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
109 Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683-692. [PMID: 20877296 DOI: 10.1038/nrclinonc.2010.154] [Cited by in Crossref: 495] [Cited by in F6Publishing: 464] [Article Influence: 45.0] [Reference Citation Analysis]
110 Lacroix-triki M, Geyer FC, Weigelt B, Reis-filho JS. Triple-Negative and Basal-like Carcinoma. Breast Pathology. Elsevier; 2012. pp. 446-78. [DOI: 10.1016/b978-1-4377-0604-8.00024-2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
111 Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014;5:125-33. [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 65] [Article Influence: 10.3] [Reference Citation Analysis]
112 Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010;46:9-20. [PMID: 19926276 DOI: 10.1016/j.ejca.2009.10.021] [Cited by in Crossref: 84] [Cited by in F6Publishing: 69] [Article Influence: 7.6] [Reference Citation Analysis]
113 Pal SK, Childs BH, Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat. 2011;125:627-636. [PMID: 21161370 DOI: 10.1007/s10549-010-1293-1] [Cited by in Crossref: 194] [Cited by in F6Publishing: 180] [Article Influence: 17.6] [Reference Citation Analysis]
114 Yamamoto Y, Iwase H. Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol 2010;15:341-51. [PMID: 20632057 DOI: 10.1007/s10147-010-0106-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
115 Johnson R, Sabnis N, McConathy WJ, Lacko AG. The potential role of nanotechnology in therapeutic approaches for triple negative breast cancer. Pharmaceutics. 2013;5:353-370. [PMID: 24244833 DOI: 10.3390/pharmaceutics5020353] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
116 Park BH, Lee SB, Stolz DB, Lee YJ, Lee BC. Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells. J Biol Chem 2011;286:20087-99. [PMID: 21467033 DOI: 10.1074/jbc.M110.191718] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
117 Gonçalves A, Sabatier R, Charafe-Jauffret E, Gilabert M, Provansal M, Tarpin C, Extra JM, Viens P, Bertucci F. [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. Bull Cancer 2013;100:453-64. [PMID: 23695030 DOI: 10.1684/bdc.2013.1740] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
118 Smith IE. Neoadjuvant/presurgical treatments. Breast Cancer Res 2008;10 Suppl 4:S24. [PMID: 19128438 DOI: 10.1186/bcr2184] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
119 Mukherjee A, Rakha EA. Integrating Breast Cancer Genetics into Clinical Practice. Womens Health (Lond Engl) 2012;8:99-112. [DOI: 10.2217/whe.11.81] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
120 Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol) 2011;23:587-600. [PMID: 21524569 DOI: 10.1016/j.clon.2011.03.013] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 6.8] [Reference Citation Analysis]
121 Johnstone TC, Kulak N, Pridgen EM, Farokhzad OC, Langer R, Lippard SJ. Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo properties. ACS Nano 2013;7:5675-83. [PMID: 23697579 DOI: 10.1021/nn401905g] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 9.1] [Reference Citation Analysis]
122 Liu M, Mo QG, Wei CY, Qin QH, Huang Z, He J. Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol Lett 2013;5:983-91. [PMID: 23426861 DOI: 10.3892/ol.2012.1093] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
123 Chen Y, Guan Y, Wang J, Ma F, Luo Y, Chen S, Zhang P, Li Q, Cai R, Li Q, Mo H, Lan B, Chen X, Zhao W, Xu B, Fan Y. Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China. Int J Cancer 2020;147:3490-9. [PMID: 32588429 DOI: 10.1002/ijc.33175] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
124 Nahleh Z. Neoadjuvant chemotherapy for “Triple Negative” breast cancer: a review of current practice and future outlook. Med Oncol 2010;27:531-9. [DOI: 10.1007/s12032-009-9244-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
125 Mccarthy N, Mitchell G, Bilous M, Wilcken N, Lindeman GJ. Triple-negative breast cancer: making the most of a misnomer: TNBC: classification and management. Asia-Pacific Journal of Clinical Oncology 2012;8:145-55. [DOI: 10.1111/j.1743-7563.2012.01533.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
126 Miles DW. Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Res 2009;11:208. [PMID: 19744307 DOI: 10.1186/bcr2237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
127 Rehman FL, Lord CJ, Ashworth A. Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010;7:718-24. [PMID: 20956981 DOI: 10.1038/nrclinonc.2010.172] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
128 Othman BA, Greenwood C, Abuelela AF, Bharath AA, Chen S, Theodorou I, Douglas T, Uchida M, Ryan M, Merzaban JS, Porter AE. Correlative Light-Electron Microscopy Shows RGD-Targeted ZnO Nanoparticles Dissolve in the Intracellular Environment of Triple Negative Breast Cancer Cells and Cause Apoptosis with Intratumor Heterogeneity. Adv Healthcare Mater 2016;5:1310-25. [DOI: 10.1002/adhm.201501012] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
129 Venkitaraman R. Triple-negative/basal-like breast cancer: clinical, pathologic and molecular features. Expert Rev Anticancer Ther 2010;10:199-207. [PMID: 20131996 DOI: 10.1586/era.09.189] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
130 Aogi K, Masuda N, Ohno S, Oda T, Iwata H, Kashiwaba M, Fujiwara Y, Kamigaki S, Ito Y, Ueno T, Takashima S. First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Res Treat 2011;129:829-38. [DOI: 10.1007/s10549-011-1685-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
131 de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183-192. [PMID: 21069385 DOI: 10.1007/s00432-010-0957-x] [Cited by in Crossref: 140] [Cited by in F6Publishing: 124] [Article Influence: 12.7] [Reference Citation Analysis]
132 Perez EA, Moreno-Aspitia A, Aubrey Thompson E, Andorfer CA. Adjuvant therapy of triple negative breast cancer. Breast Cancer Res Treat 2010;120:285-91. [PMID: 20094772 DOI: 10.1007/s10549-010-0736-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
133 Wang K, Zhuang Y, Liu C, Li Y. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K–Akt signaling. Archives of Biochemistry and Biophysics 2012;526:38-43. [DOI: 10.1016/j.abb.2012.07.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]